This cluster is routine liquidity-driven selling from option exercises. No bearish signal. Monitor for any open-market purchases by C-suite or a material increase in sale volume (>0.5% of market cap) before reassessing.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 31 $77.13entry
- T+1 · 4mo ago −0.88%α −2.31% · $76.45
- T+5 · 3mo ago −0.48%α −3.99% · $76.76
- T+20 · 3mo ago −6.53%α −9.52% · $72.09
- T+60 · 22d ago −21.26%α −23.72% · $60.73
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Robert Blum and EVP/Chief Commercial Officer Andrew Callos sold a combined $1.72M in open-market shares over a 4-day window. The CEO sale ($607K) and CCO sale ($1.12M) are both cash exercises of options followed by immediate sales, a common pattern for tax/vesting liquidity. At a $9.8B market cap, the total open-market sales represent ~0.018% of market cap, well below the 0.1% materiality threshold. The cluster is not informative per the academic literature: both sales are liquidity-driven (option exercise + sell) rather than conviction-based, and cluster sells are not predictive of negative returns. The cross-filing actuarial verdicts are all amplifiers, but the underlying event is trivial in size and structure, so no override applies.
Key Financial Metrics
Key Facts
- CEO Robert Blum sold 7,500 shares at $80.87 for $606,525 on 2026-07-27, following option exercises at $0 and $10.60 per share.
- EVP/Chief Commercial Officer Andrew Callos sold 14,000 shares at $79.88 for $1,118,320 on 2026-07-30, following option exercises at $23.26 and $0 per share.
- Total open-market sales of $1.72M represent ~0.018% of CYTK's $9.8B market cap, trivial and routine.
- Both sales are cashless option exercise-and-sell patterns, consistent with tax/vesting liquidity rather than informed selling.
- No open-market purchases were made by any insider in the cluster window.
Financial Impact
Total insider sales of $1.72M represent 0.018% of market cap, immaterial
Risk Factors
- Insider selling could accelerate if the stock price continues to appreciate, but current pattern is normal post-vesting liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1785481338492 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers